RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
November 4, 2019
RegMed Investors’ (RMi) closing bell: the market rips, the sector dips on the second session of November
November 3, 2019
RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector
October 31, 2019
RegMed Investors’ (RMi) closing bell: The sector risks are still to the downside
October 26, 2019
RegMed Investors’ (RMi) closing bell: the oversold are flirting with the upside and it ain’t a love match
October 24, 2019
RegMed Investors’ (RMi) closing bell: Low volume and percentage moves do not glamorize the sector for short-term investment
October 24, 2019
RegMed Investors’ (RMi) pre-open: futures are projecting a higher open
October 23, 2019
RegMed Investors’ (RMi) closing bell: the ceiling hasn’t fallen yet, the leaks are increasing
October 22, 2019
RegMed Investors’ (RMi) closing bell: downward motion follows yesterday’s upswing
October 21, 2019
RegMed Investors’ (RMi) closing bell: sector equities are along for the ride with market indexes
October 18, 2019
RegMed Investors’ (RMi) closing bell: escaping the maze of the oversold
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.